Ocrevus - direct healthcare professional communication (DHPC)

ocrelizumab

Despre

This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.

Documente

Direct healthcare professional communication (DHPC) : Ocrevus (ocrelizumab): New risk of drug-induced liver injury and recommendations on monitoring of liver function before and during treatment

Key facts

• Medicine name:
  Ocrevus
• Active substance:
  ocrelizumab
• Therapeutic area (MeSH):
  Multiple Sclerosis
• Procedure number:
  EMA/VR/0000313041
• Regulatory outcome:
  Variation
• DHPC type:
  • Adverse event
  • Post-authorisation measure
• Human ATC codes:
  L04AG08
• Dissemination date:
  08/10/2026